AstraZeneca may have used outdated info in coronavirus vaccine trial: US


 

Results from a US trial of AstraZeneca's COVID-19 vaccine may have used "outdated information," US federal health officials said in a statement early Tuesday.

Late Monday, the Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca may have provided an incomplete view of the efficacy data.

Late Monday, the Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca the included outdated information from that trial may have provided an incomplete view of the efficacy data.

AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that could help rebuild public confidence in the shot around the world and move it a step closer to clearance in the U.S.

In the study of 30,000 people, the vaccine was 79% effective at preventing symptomatic cases of COVID-19 including in older adults. Read More

Comments

Popular posts from this blog

Invest in smallcase with sebi registered professionals

Teji Mandi Your Ultimate Share Market App for Informed Investing

Unleashing the Potential of Stocks: Crafting a Successful Stock Portfolio